Elevance Health stock (US2855211023): earnings momentum and Medicare focus draw investor attention

Elevance Health has reported solid quarterly results and updated its outlook, while the stock reacts to shifting expectations in US health insurance and Medicare Advantage. What the latest numbers reveal about growth, margins and risks for investors.

Elevance Health has moved back into the spotlight after releasing new quarterly figures and updating its outlook for the current year. The US health insurer, formerly known as Anthem, reported rising revenue and earnings per share, driven mainly by growth in government?sponsored plans and services, according to a quarterly update published on 04/18/2024 by the company and financial media coverage on the same day Elevance Health as of 04/18/2024 and Reuters as of 04/18/2024.

In the same update, management slightly raised its full?year adjusted earnings guidance for 2024, pointing to better?than?expected performance in commercial and Medicaid membership. However, the company also highlighted higher medical costs in Medicare Advantage as a key area to monitor. The stock has traded in a relatively tight range since the release, reflecting a balance between optimism about growth and caution around regulatory and reimbursement trends.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elevance Health
• Sector/industry: Health insurance, managed care
• Headquarters/country: Indianapolis, United States
• Core markets: US commercial, Medicaid, Medicare, pharmacy and care management services
• Key revenue drivers: Membership growth, premium rates, government programs, services fees
• Home exchange/listing venue: New York Stock Exchange (ticker: ELV)
• Trading currency: US dollar (USD)

Elevance Health: core business model

Elevance Health operates as one of the largest health benefits companies in the United States, focusing on managed care and related health services. The group generates most of its revenue from health insurance premiums across commercial employer plans, individual plans and government?sponsored programs such as Medicaid and Medicare Advantage, according to its 2023 annual report released on 02/14/2024 SEC filing as of 02/14/2024.

The company works with a broad network of hospitals, physicians and other providers to design insurance products and manage medical costs for its members. It receives a fixed premium per member and aims to keep the ratio of medical claims to premiums, the medical loss ratio, within targeted ranges. Profitability therefore depends heavily on accurate pricing, risk selection and utilization management across its covered population.

Beyond traditional insurance, Elevance Health has built a diversified services portfolio under its Carelon brand. This segment includes pharmacy benefit management, behavioral health, complex care management, and technology?enabled services offered to both internal health plans and external clients. Fees from these activities are less tied to medical claims volatility and help broaden the group’s earnings base.

Elevance Health’s strategy also places emphasis on integrating data and analytics across its operations. By using claims data, clinical information and predictive models, the company seeks to identify high?risk members early, coordinate care more effectively and direct patients to cost?effective providers. Management argues that this integrated approach can improve health outcomes while supporting margin stability over time, as described in its investor presentations published on 03/11/2024 Elevance Health as of 03/11/2024.

Main revenue and product drivers for Elevance Health

A central revenue driver for Elevance Health is membership growth across its health plans. In its first?quarter 2024 release on 04/18/2024, the company reported total medical membership of roughly 48 million people, with particular strength in Medicaid and commercial risk?based plans, according to company disclosures and coverage by major news agencies on the same day Reuters as of 04/18/2024.

Premium rates and product mix also play a crucial role. Elevance Health periodically adjusts premiums in commercial and individual markets to reflect expected medical cost trends, including hospital prices, physician services and prescription drug costs. In government programs, rates are largely defined by state and federal contracts, but plan design and risk adjustment can influence realized revenue per member. A larger share of Medicare Advantage membership can support revenue growth, but also exposes the group to policy changes.

The Carelon services division adds another layer of revenue on top of premiums. In 2023, Carelon contributed several billion dollars in revenue through pharmacy benefit management, care delivery and specialty services, according to the annual report published on 02/14/2024 Elevance Health as of 02/14/2024. This unit benefits from higher utilization of specialty drugs and demand for care management, although pricing pressure from large clients and regulation of pharmacy practices represent ongoing challenges.

Cost discipline remains the counterweight to these revenue engines. The company continuously negotiates reimbursement rates with providers, promotes value?based contracts and discusses care pathways that prioritize efficient treatment settings. On the administrative side, Elevance Health invests in digital tools and automation to keep selling, general and administrative expenses as a proportion of revenue under control. Over time, small improvements in administrative efficiency can contribute meaningfully to margins given the scale of premium revenue.

Conclusion

Elevance Health remains a central player in the US managed care landscape, with significant exposure to commercial, Medicaid and Medicare Advantage markets. Recent quarterly results showed continued revenue and earnings growth, while the company modestly raised its full?year guidance in April 2024, reflecting confidence in membership trends and cost control. At the same time, management pointed to higher medical costs in Medicare Advantage and an evolving regulatory environment as key uncertainties. For US investors, the stock offers direct exposure to structural drivers such as aging demographics and expanded coverage, but performance will likely stay sensitive to policy decisions, pricing dynamics and the company’s ability to manage medical cost trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.